CTSA Visiting Scholar Seminar – Therapeutic Advances in Hereditary Hemorrhagic Telangiectasia

Join translational and clinical scientists from across the CTSA Consortium for a presentation by Hanny Al-Samkari, MD describing the revolutionary potential of anti-angiogenic therapy in hereditary hemorrhagic telangiectasia (HHT) and the evidence to date for systemic bevacizumab as a treatment for bleeding and anemia in HHT.

Registration required.

Contact Allison Rorie with any questions.